Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Sell
21
GLYC Quote, Financials, Valuation and Earnings
Last price:
$0.24
Seasonality move
:
-6.72%
Day range:
$0.21 - $0.24
52-week range:
$0.14 - $3.53
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.37x
Volume:
406.6K
Avg. volume:
1.2M
1-year change:
-90.47%
Market cap:
$15.6M
Revenue:
$10K
EPS (TTM):
-$0.62
Analysts' Opinion
-
Consensus RatingGlycoMimetics has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, GlycoMimetics has an estimated upside of 313.22% from its current price of $0.24.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $0.24.
Fair Value
-
According to the consensus of 0 analysts, GlycoMimetics has 313.22% upside to fair value with a price target of -- per share.
GLYC vs. S&P 500
-
Over the past 5 trading days, GlycoMimetics has overperformed the S&P 500 by 0.85% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
GlycoMimetics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
GlycoMimetics has grown year-over-year revenues for 1 quarter straight. In the most recent quarter GlycoMimetics reported revenues of --.
Earnings Growth
-
GlycoMimetics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter GlycoMimetics reported earnings per share of -$0.15.
Enterprise value:
1.2M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.03x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$54.2M | -$40.3M | -$36.8M | -$9.8M | -$5.7M | |
| EBITDA | -$54M | -$40.1M | -$36.7M | -$9.8M | -$5.7M | |
| Diluted EPS | -$1.02 | -$0.63 | -$0.62 | -$0.14 | -$0.15 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $145.6M | $104.1M | $53.8M | $52M | $15.6M | |
| Total Assets | $150.4M | $107.9M | $56M | $53.2M | $15.7M | |
| Current Liabilities | $9.8M | $9.7M | $7.7M | $6.4M | $4.3M | |
| Total Liabilities | $12.2M | $11.4M | $7.8M | $6.7M | $4.3M | |
| Total Equity | $138.3M | $96.6M | $48.1M | $46.5M | $11.4M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$51.4M | -$35.2M | -$35M | -$8.7M | -$8M | |
| Cash From Investing | -$86.6K | -$20.6K | -$10.8K | -$7.9K | -- | |
| Cash From Financing | $1.1M | $33M | $6.4K | $61.6K | -- | |
| Free Cash Flow | -$51.4M | -$35.2M | -$35M | -$8.7M | -$8M | |
GLYC
Sector
Market Cap
$15.6M
$46.1M
Price % of 52-Week High
6.86%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
-90.47%
-30.52%
Beta (5-Year)
1.771
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$0.23
200-day SMA
Sell
Level
$0.67
Bollinger Bands (100)
Buy
Level
0.14 - 0.32
Chaikin Money Flow
Sell
Level
-120.6M
20-day SMA
Sell
Level
$0.27
Relative Strength Index (RSI14)
Sell
Level
43.11
ADX Line
Sell
Level
13.46
Williams %R
Neutral
Level
-65.4422
50-day SMA
Sell
Level
$0.30
MACD (12, 26)
Sell
Level
-0.03
25-day Aroon Oscillator
Sell
Level
-84
On Balance Volume
Neutral
Level
1.2B
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.7731)
Sell
CA Score
(Annual)
Level (-2.562)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (10.3631)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
GlycoMimetics Inc is a clinical-stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it play in inflammation, cancer, and infection.
Stock Forecast FAQ
In the current month, GLYC has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The GLYC average analyst price target in the past 3 months is --.
-
Where Will GlycoMimetics Stock Be In 1 Year?
According to analysts, the consensus estimate is that GlycoMimetics share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About GlycoMimetics?
Analysts are divided on their view about GlycoMimetics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that GlycoMimetics is a Sell and believe this share price will drop from its current level to --.
-
What Is GlycoMimetics's Price Target?
The price target for GlycoMimetics over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is GLYC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for GlycoMimetics is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of GLYC?
You can purchase shares of GlycoMimetics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase GlycoMimetics shares.
-
What Is The GlycoMimetics Share Price Today?
GlycoMimetics was last trading at $0.24 per share. This represents the most recent stock quote for GlycoMimetics. Yesterday, GlycoMimetics closed at $0.24 per share.
-
How To Buy GlycoMimetics Stock Online?
In order to purchase GlycoMimetics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
